ReviewJournal of neurology2025
Risk factors of recurrence for epilepsy patients after antiseizure medication withdrawal: what we do and do not know?
Review in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rethinking the classification of acute status epilepticus: structural brain vs. systemic etiologies.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antiseizure medication (ASM) withdrawal has long been a tricky problem haunting patients with epilepsy and their physicians. It is important to have an accurate evaluation of recurrence risk for epilepsy patients who are seizure-free and wish to discontinue ASMs by considering relevant predictors. The purpose of this review is to summarize potential predictors based on recent research in this field. The predictors of relapse can be classified into four categories: test results, epilepsy characteristics, treatment-related factors and patient characteristics. The principal predictors are age at epilepsy onset, types of seizures, epilepsy and epilepsy syndromes, duration of seizure-free period, the number of ASMs and abnormal electroencephalography (EEG).The decisions of ASM withdrawal should be based on predictors and patients' conditions and expectations. A discussion of ASM withdrawal must be made among patients, caregivers and physicians to make sure the benefits outweigh the risks. Future studies should explore the underlying mechanisms of relapse and the interactions among different predictors. They should also aim to identify more risk factors, improve the quality of studies and include diverse outcome measurements.
Indexed as
Identifiers
41134431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.